ENDEAVOR: A phase 3 study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr Jesús San Miguel at EHA 2015
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label,...
Author: EMJ
Added: 06/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2015 Category: Cancer & Oncology Source Type: podcasts
Results of the phase 3 ELOQUENT-2 trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Prof Sagar Lonial at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label ...
Author: EMJ
Added: 06/19/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 19, 2015 Category: Cancer & Oncology Source Type: podcasts
EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression or death
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints of ...
Author: EMJ
Added: 06/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase II MM-014 Trial of POM+LoDEX in RRMM
A phase II trial (MM-014) evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line len...
Author: feeds
Added: 05/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Oprozomib & Dexamethasone in Patients w/Relapsed and/or Refractory Myeloma
Dr. Parameswaran discusses Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open...
Author: feeds
Added: 05/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Safety & Efficacy of the STRATUS (MM-010) Trial
Dr. Meletios discusses a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
Author: feeds
Added: 05/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Patients with MM: Elotuzumab With Lenalidomide& Dexamethasone
Phase 1b Study (Abstract 2119).
At ASH 2014, Dr. Jesus Berdeja discussed his abstract on Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with ...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
- Relapsed & Refractory Myeloma: Pomalidomide, Cyclophosphamide, Dex. Superior to Pomalidomide & Dex.
Randomized Phase II Study (Abstract 303).
At ASH 2014, Dr. Rachid Baz discussed his abstract titled Results of a Multicenter Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidom...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Patients w/ Relapsed or Relapsed/Refractory MM: Ibrutinib, Single Agent or Combination w/ Dexamethasone
Preliminary Phase 2 Results (Abstract 31): Dr. Ravi Vij discussed his abstract titled Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Mul...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr. Kumar discusses Ixazomib Combo for Multiple Myeloma Treatment
Dr. Kumar discusses the use of the proteasome inhibitor Ixazomib in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Shaji Kumar, MD, ...
Author: onclivetv
Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Ola Landgren at ASH 2014: Final results from NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in high-risk smouldering myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren discusses the final results from the NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in 12 pati...
Author: EMJ
Added: 01/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jeffery Matous at ASH 2014: Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous ((Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE stu...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jeffery Matous at ASH 2014: Phase I MM-008 study of pomalidomide and dexamethasone in relapsed/refractory myeloma with renal impairment
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses combination approaches and novel monoclonal antibodies in mul...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jeffery Matous at ASH 2014: Phase I MM-008 study of pomalidomide and dexamethasone in relapsed/refractory myeloma and renal impairment
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the multicentre, open-label, phase I MM-008 study that is ass...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Maria-Victoria Mateos at ASH 2014: Follow up on a phase III study of lenalidomide plus low-dose dexamethasone in high-risk smouldering myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos provides an update of a randomised, phase III study, which was initiated in 2007, of lenalidomide plus low-dos...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
